Stock Ratings / Health Care / LMAT / options

XRAY (46) INSP (61) KMTS (43) ATEC (38) ⌘ Pro Terminal →

LeMaitre Vascular Inc. (LMAT) Options Positioning, Max Pain & Unusual Sweeps

$85.27 +2.90% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

LeMaitre Vascular Inc. (LMAT) earns a Roarable Rating of B (Buy) with 74/100 RQD Confidence. High-quality cash engine (72% profit margin, 15% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $1.95B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERBUY • B

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+7.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LMAT)Realized 20D OHLCV Swing Band: ±6.1%

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±6.1%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (LMAT)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for LMAT.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating LMAT & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on LMAT
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LMAT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -22.31%⚡ TESTING RESISTANCE

2026-10-30O $85.53H $85.53L $80.03C $85.27VOL 427.4K

RES: $86.11SUP: $78.19SMA50: $81.20SMA200: $94.47

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LMAT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LMAT Butterfly Map → + Track LMAT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

26.1%/yr Implied 5Y Growth

vs. +13.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LMAT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LMAT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LMAT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LMAT)

Health Care Rank #54 of 1016 ⚔️ XRAY vs LMAT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LMAT vs. XRAY, INSP, KMTS, ATEC)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, LeMaitre Vascular Inc. (LMAT) ranks #54 by composite RQD confidence (74/100, grade B) and #268 by equity capitalization ($1.95B). Within this direct 5-issuer industry benchmark cohort, INSP leads on earnings valuation at 14.2x trailing P/E, while LMAT leads on capital efficiency and profitability with 14.7% ROIC and 71.5% gross margin. LMAT currently leads its immediate peer cohort in composite quantitative strength at 74/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LMAT ACTIVE LeMaitre Vascular Inc.	B	74/100	33.8x	71.5%	14.7%	+2.90%	$1.95B	Benchmark Subject
XRAY DENTSPLY SIRONA Inc.	D	46/100	—	50.0%	-11.0%	+1.80%	$1.92B	/xray-vs-lmat →
INSP Inspire Medical Systems Inc.	C-	61/100	14.2x	85.4%	6.0%	+0.30%	$2.06B	/insp-vs-lmat →
KMTS Kestra Medical Technologies Ltd.	D-	43/100	—	51.4%	-35.0%	+2.48%	$1.82B	/kmts-vs-lmat →
ATEC Alphatec Holdings Inc.	D-	38/100	—	69.6%	-18.4%	-0.70%	$1.76B	/atec-vs-lmat →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001158895

In its most recent audited fiscal period (FY2025, filed 2025-12-31), LeMaitre Vascular Inc. (LMAT) reported GAAP revenue of $249.6M (+13.5% vs. FY2024 revenue of $219.9M , and +29.0% cumulative change since FY2023) , GAAP net income of $57.7M, operating cash flow of $81.3M, and free cash flow of $81.3M (+84.1% YoY). On the balance sheet, LMAT closed FY2025 with $615.7M in total assets against $0 in total debt (Altman Z-Score: 7.30, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$249.6M	$57.7M	$81.3M	$81.3M	$615.7M	—
FY2024 (FY)	2024-12-31	$219.9M	$44.0M	$44.1M	$44.1M	$551.8M	—
FY2023 (FY)	2023-12-31	$193.5M	$30.1M	$36.8M	$36.8M	—	—

3. LMAT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LMAT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, LeMaitre Vascular Inc. (NASDAQ: LMAT) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $85.27 (+2.90% 1D, market cap $1.95B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, LMAT ranks #54 in composite RQD confidence.

How does LMAT compare to XRAY and INSP in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), LMAT carries a Roarable B (74/100 RQD), trailing P/E of 33.8x, gross margin of 71.5%, and ROIC of 14.7%. By comparison, XRAY (DENTSPLY SIRONA Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -11.0%, cap $1.92B) and INSP (Inspire Medical Systems Inc.) posts a C- grade (61/100 RQD, P/E 14.2x, ROIC 6.0%, cap $2.06B). Among the 5-stock peer group, INSP leads on earnings multiple (14.2x) while LMAT leads on capital efficiency (14.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LMAT?

Per LMAT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001158895), LeMaitre Vascular Inc. generated $249.6M in revenue (+13.5% YoY), $57.7M in net income, and $81.3M in free cash flow against $615.7M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (72% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LMAT trading relative to its 50-day, 200-day, and 52-week technical levels?

LMAT last traded at $85.27 (+2.90% on volume of 300,147 shares), positioning the stock +5.01% above its 50-day simple moving average ($81.20) and -9.74% below its 200-day simple moving average ($94.47). Across its 52-week range of $78.22 to $118.01, LMAT sits at the 17.7% percentile with a 14-day RSI of 45.4 (NEUTRAL RANGE) and an implied next-earnings move of ±6.1% ($80.07 to $90.47).

LMAT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is LMAT's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for LMAT.

Direct Sub-Reports: LMAT RQD Cockpit LMAT 12M Forecast LMAT Earnings & Move LMAT Dividends & DRIP LMAT Insiders & 13F LMAT Whale Options LMAT Profit Sankey LMAT News & Why